EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 39 / Numéro 5 (Mai 2023) Med Sci (Paris), 39 5 (2023) 429-436 Références
Open Access
Numéro
Med Sci (Paris)
Volume 39, Numéro 5, Mai 2023
Page(s) 429 - 436
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2023058
Publié en ligne 23 mai 2023
  1. Speakman M, Kirby R, Doyle S, Ioannou C. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK. BJU Int 2015 ; 115 : 508–519. [CrossRef] [PubMed] [Google Scholar]
  2. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003 ; 349 : 2387–2398. [CrossRef] [PubMed] [Google Scholar]
  3. Ploussard G, Roubaud G, Barret E, et al. French AFU Cancer Committee Guidelines - Update 2022–2024 : prostate cancer - Management of metastatic disease and castration resistance. Prog Urol 2022; 32 : 1373–419. [CrossRef] [PubMed] [Google Scholar]
  4. James ND, de Bono JS, Spears MR, et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med 2017 ; 377 : 338–351. [CrossRef] [PubMed] [Google Scholar]
  5. Fizazi K, Tran N, Fein L, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 2017 ; 377 : 352–360. [CrossRef] [PubMed] [Google Scholar]
  6. Armstrong AJ, Azad AA, Iguchi T, et al. Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 2022; 40 : 1616–22. [CrossRef] [PubMed] [Google Scholar]
  7. INCa. Panorama des cancers en France. https://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Panorama-des-cancers-en-France-Edition-20222022. [Google Scholar]
  8. Strand DW, Costa DN, Francis F, et al. Targeting phenotypic heterogeneity in benign prostatic hyperplasia. Differentiation 2017 ; 96 : 49–61. [CrossRef] [PubMed] [Google Scholar]
  9. Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes Dev 2000 ; 14 : 2410–2434. [CrossRef] [PubMed] [Google Scholar]
  10. Zhang D, Zhao S, Li X, et al. Prostate Luminal Progenitor Cells in Development and Cancer. Trends Cancer 2018 ; 4 : 769–783. [CrossRef] [PubMed] [Google Scholar]
  11. Sibony M. Pratique en anatomopathologie. La prostate. Paris : Sauramps médical, 2018 : 236p. [Google Scholar]
  12. Choi N, Zhang B, Zhang L, et al. Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. Cancer Cell 2012 ; 21 : 253–265. [CrossRef] [PubMed] [Google Scholar]
  13. Liu J, Pascal LE, Isharwal S, et al. Regenerated luminal epithelial cells are derived from preexisting luminal epithelial cells in adult mouse prostate. Mol Endocrinol 2011 ; 25 : 1849–1857. [CrossRef] [PubMed] [Google Scholar]
  14. Ousset M, Van Keymeulen A, Bouvencourt G, et al. Multipotent and unipotent progenitors contribute to prostate postnatal development. Nat Cell Biol 2012 ; 14 : 1131–1138. [CrossRef] [PubMed] [Google Scholar]
  15. Wang ZA, Toivanen R, Bergren SK, et al. Luminal cells are favored as the cell of origin for prostate cancer. Cell Rep 2014 ; 8 : 1339–1346. [CrossRef] [PubMed] [Google Scholar]
  16. Wang X, Kruithof-de Julio M, Economides KD, et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 2009 ; 461 : 495–500. [CrossRef] [PubMed] [Google Scholar]
  17. Baures M, Dariane C, Tika E, et al. Prostate luminal progenitor cells : from mouse to human, from health to disease. Nat Rev Urol 2022; 19 : 201–18. [CrossRef] [PubMed] [Google Scholar]
  18. Mevel R, Steiner I, Mason S, et al. RUNX1 marks a luminal castration-resistant lineage established at the onset of prostate development. Elife 2020; 9. [Google Scholar]
  19. Karthaus WR, Hofree M, Choi D, et al. Regenerative potential of prostate luminal cells revealed by single-cell analysis. Science 2020; 368 : 497–505. [CrossRef] [PubMed] [Google Scholar]
  20. Crowley L, Cambuli F, Aparicio L, et al. A single-cell atlas of the mouse and human prostate reveals heterogeneity and conservation of epithelial progenitors. Elife 2020; 9. [Google Scholar]
  21. Guo W, Li L, He J, et al. Single-cell transcriptomics identifies a distinct luminal progenitor cell type in distal prostate invagination tips. Nat Genet 2020; 52 : 908–18. [CrossRef] [PubMed] [Google Scholar]
  22. Joseph DB, Henry GH, Malewska A, et al. Urethral luminal epithelia are castration-insensitive cells of the proximal prostate. Prostate 2020; 80 : 872–84. [CrossRef] [PubMed] [Google Scholar]
  23. Baures M, Puig Lombardi E, Di Martino D, et al. Transcriptomic Signature and Growth Factor Regulation of Castration-Tolerant Prostate Luminal Progenitor Cells. Cancers (Basel) 2022; 14 : 3775. [CrossRef] [PubMed] [Google Scholar]
  24. Sackmann Sala L, Boutillon F, Menara G, et al. A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumors. J Pathol 2017; 243 : 54–64. [Google Scholar]
  25. Sackmann-Sala L, Chiche A, Mosquera-Garrote N, et al. Prolactin-Induced Prostate Tumorigenesis Links Sustained Stat5 Signaling with the Amplification of Basal/Stem Cells and Emergence of Putative Luminal Progenitors. Am J Pathol 2014 ; 184 : 3105–3119. [CrossRef] [PubMed] [Google Scholar]
  26. Kwon OJ, Zhang L, Xin L. Stem Cell Antigen-1 Identifies a Distinct Androgen-Independent Murine Prostatic Luminal Cell Lineage with Bipotent Potential. Stem Cells 2016 ; 34 : 191–202. [CrossRef] [PubMed] [Google Scholar]
  27. Liu X, Grogan TR, Hieronymus H, et al. Low CD38 Identifies Progenitor-like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome. Cell Rep 2016 ; 17 : 2596–2606. [CrossRef] [PubMed] [Google Scholar]
  28. Joseph DB, Turco AE, Vezina CM, Strand DW. Progenitors in prostate development and disease. Dev Biol 2021; 473 : 50–8. [CrossRef] [PubMed] [Google Scholar]
  29. Carver BS, Chapinski C, Wongvipat J, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011 ; 19 : 575–586. [CrossRef] [PubMed] [Google Scholar]
  30. Chan JM, Zaidi S, Love JR, et al. Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling. Science 2022; 377 : 1180–91. [CrossRef] [PubMed] [Google Scholar]
  31. Henry GH, Malewska A, Joseph DB, et al. A Cellular Anatomy of the Normal Adult Human Prostate and Prostatic Urethra. Cell Rep 2018 ; 25 : 3530–42e5. [CrossRef] [PubMed] [Google Scholar]
  32. Rawlins EL, Okubo T, Xue Y, et al. The role of Scgb1a1+ Clara cells in the long- term maintenance and repair of lung airway, but not alveolar, epithelium. Cell Stem Cell 2009 ; 4 : 525–534. [CrossRef] [PubMed] [Google Scholar]
  33. Hirz T, Mei S, Sarkar H, et al. Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses. Nat Commun 2023; 14 : 663. [CrossRef] [PubMed] [Google Scholar]
  34. Joseph DB, Henry GH, Malewska A, et al. 5-alpha reductase inhibitors induce a prostate luminal to club cell transition in human benign prostatic hyperplasia. J Pathol 2022; 256 : 427–41. [CrossRef] [PubMed] [Google Scholar]
  35. Song H, Weinstein HNW, Allegakoen P, et al. Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states. Nat Commun 2022; 13 : 141. [CrossRef] [PubMed] [Google Scholar]
  36. Chen S, Zhu G, Yang Y, et al. Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression. Nat Cell Biol 2021; 23 : 87–98. [CrossRef] [PubMed] [Google Scholar]
  37. Dariane C, Clairefond S, Peant B, et al. High Keratin-7 Expression in Benign Peri-Tumoral Prostatic Glands Is Predictive of Bone Metastasis Onset and Prostate Cancer-Specific Mortality. Cancers (Basel) 2022; 14 : 1623. [CrossRef] [PubMed] [Google Scholar]
  38. Han H, Wang Y, Curto J, et al. Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis. Cell Rep 2022; 39 : 110595. [CrossRef] [PubMed] [Google Scholar]
  39. Barron DA, Rowley DR. The reactive stroma microenvironment and prostate cancer progression. Endocr Relat Cancer 2012 ; 19 : R187–R204. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.